Skip to main content
. 2021 Jan 1;11(6):2634–2654. doi: 10.7150/thno.53139

Figure 8.

Figure 8

D-Nap-GFFY-T317 blocks hypertriglyceridemia and fatty liver induced by the long-term of T317 treatment in both WT and IFNγ-/- mice. Blood and liver samples were collected from mice used in Figure 6, and conducted the following assays. (A) serum TG levels were determined using an assay kit. (B-C) liver was photographed, and weighed, followed by calculation of the ratio of liver weight to body weight. (D-E) lipid content in the liver was determined by Oil Red O staining of liver frozen sections and TG quantitative assay with total lipid extracted from a piece of liver (normalized by liver protein content). (F-G) expression of LXRα and LXRβ, FASN and nSREBP1 protein in the liver was determined by Western blot. (A, C-D): *P < 0.05, **P < 0.01, ***: P < 0.001; NS: not significantly different. n = 14 for WT mice, n ≥ 8 for IFNγ-/- mice as indicated in Table 2; (F-G): *P < 0.05 vs. NC, ^P < 0.05 vs. TF, n = 4.